These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29025746)

  • 1. Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation.
    Williams BA; Evans MA; Honushefsky AM; Berger PB
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29025746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.
    Hirano T; Kaneko H; Mishina S; Wang F; Morita S
    J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2102-2110. PubMed ID: 28532651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified application of SAMe-TT2R2 scoring system in Asian patients with atrial fibrillation for the selection of oral anticoagulants.
    Jeon SW; Lee N; Lee KH; Ha M; Kim C; Kim YR; Yoon NS; Park HW
    Korean J Intern Med; 2024 May; 39(3):458-468. PubMed ID: 38287499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: perspectives from the observational, prospective WATER Registry.
    Turk UO; Tuncer E; Alioglu E; Yuksel K; Pekel N; Ozpelit E; Vuran O; Tengiz I
    Cardiol J; 2015; 22(5):567-75. PubMed ID: 26100825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of unstable anticoagulation with acenocoumarol versus warfarin in atrial fibrillation.
    Bryk AH; Plens K; Undas A
    Cardiol J; 2017; 24(5):477-483. PubMed ID: 28353307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors for INR-control in a well-managed warfarin treatment setting.
    Björck F; Kadhim H; Själander A
    J Thromb Thrombolysis; 2019 Feb; 47(2):227-232. PubMed ID: 30411185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.
    Singer DE; Hellkamp AS; Piccini JP; Mahaffey KW; Lokhnygina Y; Pan G; Halperin JL; Becker RC; Breithardt G; Hankey GJ; Hacke W; Nessel CC; Patel MR; Califf RM; Fox KA;
    J Am Heart Assoc; 2013 Feb; 2(1):e000067. PubMed ID: 23525418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction Score for Anticoagulation Control Quality Among Older Adults.
    Lin KJ; Singer DE; Glynn RJ; Blackley S; Zhou L; Liu J; Dube G; Oertel LB; Schneeweiss S
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28982676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score.
    Apostolakis S; Sullivan RM; Olshansky B; Lip GYH
    Chest; 2013 Nov; 144(5):1555-1563. PubMed ID: 23669885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Tasmanian atrial fibrillation study: Transition to direct oral anticoagulants 2011-2015.
    Alamneh EA; Chalmers L; Bereznicki LR
    Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28177198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial.
    Singer DE; Hellkamp AS; Yuan Z; Lokhnygina Y; Patel MR; Piccini JP; Hankey GJ; Breithardt G; Halperin JL; Becker RC; Hacke W; Nessel CC; Mahaffey KW; Fox KA; Califf RM;
    J Am Heart Assoc; 2015 Mar; 4(3):e001349. PubMed ID: 25736441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists.
    Ruiz-Ortiz M; Bertomeu V; Cequier Á; Marín F; Anguita M
    Thromb Haemost; 2015 Oct; 114(4):695-701. PubMed ID: 26054407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of the SAMe-TT2R2 Score to Predict Good Anticoagulation Control with Warfarin in Chinese Patients with Atrial Fibrillation: Relationship to Ischemic Stroke Incidence.
    Chan PH; Hai JJ; Chan EW; Li WH; Tse HF; Wong IC; Lip GY; Siu CW
    PLoS One; 2016; 11(3):e0150674. PubMed ID: 27010633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation.
    Lind M; Fahlén M; Kosiborod M; Eliasson B; Odén A
    Thromb Res; 2012 Jan; 129(1):32-5. PubMed ID: 21851969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving Anticoagulation Measurement Novel Warfarin Composite Measure.
    Razouki Z; Burgess JF; Ozonoff A; Zhao S; Berlowitz D; Rose AJ
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):600-7. PubMed ID: 26420820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial.
    Piccini JP; Hellkamp AS; Lokhnygina Y; Patel MR; Harrell FE; Singer DE; Becker RC; Breithardt G; Halperin JL; Hankey GJ; Berkowitz SD; Nessel CC; Mahaffey KW; Fox KA; Califf RM;
    J Am Heart Assoc; 2014 Apr; 3(2):e000521. PubMed ID: 24755148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction.
    Szummer K; Gasparini A; Eliasson S; Ärnlöv J; Qureshi AR; Bárány P; Evans M; Friberg L; Carrero JJ
    J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28249846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control.
    Janzic A; Kos M
    Pharmacoeconomics; 2015 Apr; 33(4):395-408. PubMed ID: 25512096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation.
    Clarkesmith DE; Pattison HM; Lane DA
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008600. PubMed ID: 23736948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.